Epidermal Growth Factor Receptor Antagonist class drugs
1 result
Portrazza (necitumumab)
(necitumumab)Eli Lilly and Company
Usage: PORTRAZZA™ is indicated for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin. It is not intended for non-squamous NSCLC.